New Financial Aid Helps Researchers Work In Order To Speed Up the Discovery of Cancer Drugs
The CPRIT (Cancer Prevention Research Institute Of Texas) have given grants to doctors Maria Person and Kelvin Dalby. These grants are to aid the doctor's work in their research to increase our understanding of the biology of cancerous cells and to aid in the development of novel cancer treatments.
Doctor Kelvin Dalby who is an associate professor of medical chemistry was given two point four million United States dollars in order to further support his work at the university's Texas based institute for drug and diagnostic development. This was given through the twelve point six million United States Dollar grant that was given to the Gulf Coast Consortia CPRIT thorough put screening program. Doctor Kelvin Dalby is the director of this consortium.
The consortia is expected to give researchers access to many medical resources including chemical library screening and robotic machinery, this type of equipment is usually only available to researchers and scientists who work for very large pharmaceutical companies.
One of the laboratories that researchers will have access to has been dubbed 'the Dalby laboratory' named of course from Doctor Kelvin Dalby. This laboratory will mainly centre its studies of comprehending the part that protein kinases play in cancer development. These protein kinases are a category of enzymes that control cellular signalling and are therefore thought to be the most significant drug and medicine target of the twenty first century. The dalby labratory is currently developing new compounds that will restrict the activities of protein kinases, these can in theory be used therapeutically in addition to being used to aid in the comprehension of cancer mechanisms.
Doctor Kelvin Dalby says that the chief goal of his research team is to facilitate for the provision of realistic methods towards the development of novel drugs. He went on to say that the work of his research team in Austin will further utilise the strengths of the team at the university in biochemistry, chemo-informatics and medicinal chemistry.
A grant of one point three million dollars was received by Doctor Person, the director of the institute for cellular and molecular biology and college of pharmacy's protein and metabolite analysis facility. This grant was used to procure modern mass spectrometry equipment. The work of Doctor Person is done in collaboration with other researchers at the M.D Anderson Cancer Centre and at the University itself. The work of Doctor Person is aimed at the comprehension of cancer at the molecular level, in human population studies and in animal models.
The Doctor says that their main aim is to facilitate for the improvement of the way in which ovarian cancer, leukemia, pancreatic cancer, lymphomas and breast cancers are detected and treated.
The modern equipment purchased by Doctor Person's research team from the grant money they received will be utilised in the observation of molecular details ranging from early stage DNA damage, to cell proliferation, invasion and metastasis. This equipment will also be used to enable the provision of highly detailed characterization of the way in which drugs interact with DNA and proteins.
Dean Lynn Crismon said that Doctor Kelvin Dalby's cancer drug development will significantly aid efforts to find cancer drugs at the university. He went on to say that one of the main goals of the university is for one of their members to produce a compound that will turn out to be the cure for cancer.
Dean Lynn Crismon also stated that he feels that the university is committed to the development of a new cancer drug from the bedside to the research lab bench.
In conclusion Dean Lynn Crismon says that the equipment obtained from Dr Person's grant will greatly enhance the things that the universities protein and metabolic facility is capable of. Furthermore he said the equipment would be useful not only in the basic discovery of drugs but also in preclinical drug development. Therefore the two grants are indicative of progress in the universities ability to carry out state-of-the-art cancer research.